Genmab — Februar 2021
-
Desværre ikke - det har Blue slet ikke mcap til at gøre
-
God morgen.
-
Asien: Asiatiske aktier uden ensartet
retning: https://www.proinvestor.com/investornyt/672202/asien-asiatiske-aktier-uden-ensartet-retning -
Onsdagens aviser med ATP, PFA og kapitalfonde: https://www.proinvestor.com/investornyt/672201/onsdagens-aviser-med-atp-pfa-og-kapitalfonde
-
-
Lider bio-pharma lidt under en Bluebird forskrækkelse her til morgen?
-
to rub it in, Novartis and the Gates Foundation are joining forces to discover and develop a gene therapy to cure sickle cell disease https://www.statnews.com/2021/02/17/novartis-gates-foundation-aim-to-create-more-practical-sickle-cell-gene-therapy/
-
That may be the future - gene therapy or manipulation which lead the present value adjustment today/yesterday?
-
I wasn
-
was not looking for 1 to 1 connect. in that term. But it seems like people forget the risk and then having a wakeup call suddenly which also w
ill affect peers -
should be brief. As you mention Genmab has a broad foundation that has been recognized by value in the market
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind